HSBC Downgrades Thermo Fisher Scientific to Hold, Cuts Price Target
HSBC downgraded Thermo Fisher Scientific (TMO) from Buy to Hold and cut its price target from $670 to $540, citing difficulties in achieving 7% growth.
Key Numbers
HSBC downgraded Thermo Fisher Scientific Inc. (NYSE:TMO) from Buy to Hold and lowered its price target to $540 from $670, according to an Insider Monkey report dated June 9, 2026.
Rating Change
| Item | Before | After |
|---|---|---|
| Rating | Buy | Hold |
| Price Target | $670 | $540 |
Analyst Rationale
The HSBC analyst cited challenges in Thermo Fisher achieving its goal of returning to 7% growth as the primary reason for the downgrade and price target cut. The current valuation also does not offer an attractive enough entry point for near-term investors.
Context
The downgrade comes after billionaire investor Ken Fisher included TMO among his top 11 dividend stock picks. However, HSBC's cautious stance reflects broader concerns about the pace of recovery in the life sciences sector post-pandemic.
Conclusion
HSBC's downgrade does not necessarily mean TMO is a bad stock, but rather reflects more conservative near-term growth expectations. Investors should monitor quarterly results and any updates on the company's growth strategy.
Frequently Asked Questions
Found this useful? Share it